Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
Enanta Pharmaceuticals (NAS:ENTA) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Enanta Pharmaceuticals's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
14.08
/
17.16
=
0.82
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enanta Pharmaceuticals Median PS Value Related Terms
Enanta Pharmaceuticals Median PS Value Historical Data
* Premium members only.
The historical data trend for Enanta Pharmaceuticals's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ENTA vs CMPX, CCCC, LXEO: Median PS Value Comparison
For the Biotechnology subindustry, Enanta Pharmaceuticals's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Enanta Pharmaceuticals Price-to-Median-PS-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Enanta Pharmaceuticals's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Enanta Pharmaceuticals's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 7.0299.
Enanta Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.441.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enanta Pharmaceuticals (ENTA) has a Median PS Value of $17.16 as of Aug. 26, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Enanta Pharmaceuticals and its competitors. According to the industry distribution chart, Enanta Pharmaceuticals ranks #177 out of 281 companies in the Biotechnology industry, placing it in the top 63%.
Is Enanta Pharmaceuticals' Median PS Value too high?
Enanta Pharmaceuticals' current Median PS Value is $17.16. The Biotechnology industry median Median PS Value is 0.64. Enanta Pharmaceuticals' value of $17.16 is 2581.3% above this industry median. Based on the distribution chart, Enanta Pharmaceuticals ranks #177 out of 281 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Enanta Pharmaceuticals has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Enanta Pharmaceuticals' Median PS Value compare to CMPX and CCCC?
According to the Biotechnology industry distribution chart, Enanta Pharmaceuticals ranks #177 out of 281 companies for Median PS Value. This places Enanta Pharmaceuticals in the lower half of its industry. The industry median Median PS Value is 0.64. Enanta Pharmaceuticals' value of $17.16 is 2581.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Biotechnology company?
The median Median PS Value among Biotechnology companies is 0.64, based on 281 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Enanta Pharmaceuticals's current Median PS Value of $17.16 is 2581.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Enanta Pharmaceuticals and its competitors. For the Biotechnology industry, the median Median PS Value is 0.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Enanta Pharmaceuticals's current Median PS Value is $17.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enanta Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Enanta Pharmaceuticals (ENTA) is currently considered Significantly Overvalued. The stock's GF Value™ is $7.93, compared to a current price of $14.08 — trading 77.6% above its estimated fair value. The current Median PS Value is $17.16 and 2581.3% above the Biotechnology industry median of 0.64. Enanta Pharmaceuticals' overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Enanta Pharmaceuticals (ENTA), the current Median PS Value is $17.16 as of Aug. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Enanta Pharmaceuticals (ENTA) Overvalued in 2026?
Based on GuruFocus' analysis, Enanta Pharmaceuticals stock appears to be overvalued.
The current stock price of $14.08 is trading 77.6% above its estimated GF Value™ of $7.93.
GuruFocus considers Enanta Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for ENTA:
Median PS Value: $17.16
GF Value™: $7.93 vs. price of $14.08 (77.6% above fair value)
Industry Position: 2581.3% above the Biotechnology median (#177 of 281)
No single metric tells the full story. See the ENTA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.
49GF Score
Get the complete analysis for ENTA
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ENTA has been successfully added to your 
